Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Neurogene's enterprise value was $171.95M on Nov 11, 2026, against $45.71M a year earlier. Over the last 5 years it ranged from -$138.45M to $1.08B, with a median of $94.86M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $171.95M | +345.2% |
| 2025 | Dec 31, 2025 | $38.62M | -75.6% |
| 2024 | Dec 31, 2024 | $158.10M | +120.2% |
| 2023 | Dec 29, 2023 | $71.80M | – |
| 2022 | Dec 30, 2022 | -$21.03M | -103.2% |
| 2021 | Dec 31, 2021 | $662.21M | -69.3% |
| 2020 | Dec 31, 2020 | $2.16B | +63.6% |
| 2019 | Dec 31, 2019 | $1.32B | +1032.1% |
| 2018 | Dec 31, 2018 | $116.63M | -89.0% |
| 2017 | Dec 29, 2017 | $1.06B | -27.7% |
| 2016 | Dec 30, 2016 | $1.46B | +94.8% |
| 2015 | Dec 31, 2015 | $749.85M | +413.1% |
| 2014 | Dec 31, 2014 | $146.15M | – |
See a number that looks wrong?